Sign in →

Test Code CVHBG Comprehensive Cerebrovascular Gene Panel, Varies


Ordering Guidance


Customization of this panel and single gene analysis for any gene present on this panel are available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.

 

Targeted testing for familial variants (also called site-specific or known mutations testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.



Shipping Instructions


Specimen preferred to arrive within 96 hours of collection.



Necessary Information


Prior Authorization is available, but not required, for this test. If proceeding with the prior authorization process, submit the required form with the specimen.



Specimen Required


Patient Preparation:  A previous bone marrow transplant from an allogenic donor will interfere with testing. For instructions for testing patients who have received a bone marrow transplant, call 800-533-1710.

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred)/Refrigerated


Forms

1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file.

The following documents are available:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing (Spanish) (T826)

2. Connective Tissue/Cerebrovascular Disease Genetic Testing Patient Information

3. Cerebrovascular Gene Panel (CVHBG) Prior Authorization Ordering Instructions

Useful For

Providing a genetic evaluation for patients with a personal or family history suggestive of a monogenic condition in which there is an increased risk for a cerebrovascular accident

 

Establishing a diagnosis of a monogenic condition in which there is an increased risk for a cerebrovascular accident

Genetics Test Information

This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 30 genes associated with monogenic conditions in which there is an increased risk for cerebrovascular accident (stroke): ACTA2, ACVRL1, ADA2, CBS, CCM2, COL3A1, COL4A1, COL4A2, CST3, ENG, EPHB4, GDF2, GLA, GUCY1A1, HTRA1, KRIT1, NOTCH3, PDCD10, RASA1, RNF213, SLC2A10, SMAD2, SMAD3, SMAD4, TEK, TGFB2, TGFB3, TGFBR1, TGFBR2, and TREX1. See Targeted Genes and Methodology Details for Comprehensive Cerebrovascular Gene Panel and Method Description for additional details.

 

Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, familial screening, and genetic counseling for monogenic conditions in which there is an increased risk for a cerebrovascular accident (stroke).

 

Prior Authorization is available for this assay.

Disease States

  • Homocystinuria

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing

Reporting Name

Cerebrovascular Gene Panel

Specimen Type

Varies

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

There are many known monogenic conditions that increase an individual's risk for cerebrovascular accident or stroke. Most of these conditions are characterized by abnormal vascular development, abnormal intracranial blood flow, and weakening of the cerebral vessels. Depending on the pathophysiology of the associated condition, risk may be increased for ischemic stroke, hemorrhagic stroke, or both.(1)

 

Several vascular malformation syndromes are associated with an increased risk for stroke due to abnormalities in vascular development throughout the body.(1) Pulmonary arteriovenous malformations (AVM) are common features of autosomal dominant hereditary hemorrhagic telangiectasia and autosomal dominant capillary malformation-AVM. Pulmonary AVM increase the risk for ischemic stroke by allowing emboli to bypass the lungs and enter the cerebral vasculature.(1) Autosomal dominant familial cerebral cavernous malformation causes abnormal development of capillary channels within the brain and is associated with an increased risk for hemorrhagic stroke.(1,2)

 

Several monogenic connective tissue conditions leading to vascular fragility are associated with an increased risk for arterial dissection and ischemic stroke.(1) These conditions lead to defects impacting the structural integrity of blood vessels throughout the body resulting in a high risk for vessel rupture. This panel assesses several vascular fragility syndromes, including autosomal dominant vascular Ehlers-Danlos syndrome, autosomal dominant Loeys-Dietz syndrome, autosomal dominant familial aortic aneurysm and dissection, and autosomal recessive arterial tortuosity syndrome.(3-6)

 

Hereditary cerebral small vessel disease (SVD) is a group of conditions generally characterized by lacunar infarcts and white matter hyperintensities on magnetic resonance imaging and an increased risk for ischemic and/or hemorrhagic stroke.(1,7) The monogenic SVDs assessed on this panel include cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), autosomal dominant retinal vasculopathy with leukodystrophy, autosomal dominant COL4A1-associated SVD, and autosomal dominant COL4A2-associated SVD.(1, 7)

 

Moyamoya disease, a condition characterized by progressive narrowing of the blood vessels and an increased risk for ischemic stroke, can be inherited in an autosomal dominant manner. However, in most individuals, the genetic etiology (if any) remains unknown.(1,8)

 

Other conditions associated with increased risk for ischemic and hemorrhagic stroke assessed on this panel include X-linked Fabry disease, autosomal recessive homocystinuria due to variants in the CBS gene, and autosomal recessive adenosine deaminase 2 deficiency.(1,9)

Reference Values

An interpretive report will be provided.

Interpretation

All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(10) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

Day(s) Performed

Varies

Report Available

28 to 42 days

Specimen Retention Time

Whole blood: 2 weeks (if available); Extracted DNA: 3 months

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

81405 x5

81406 x3

81408

81479

81479 (if appropriate for government payers)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CVHBG Cerebrovascular Gene Panel 55232-3

 

Result ID Test Result Name Result LOINC Value
617226 Test Description 62364-5
617227 Specimen 31208-2
617228 Source 31208-2
617229 Result Summary 50397-9
617230 Result 82939-0
617231 Interpretation 69047-9
617232 Additional Results 82939-0
617233 Resources 99622-3
617234 Additional Information 48767-8
617235 Method 85069-3
617236 Genes Analyzed 48018-6
617237 Disclaimer 62364-5
617238 Released By 18771-6